Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Transplant for Germ Cell Tumors
NCT00432094Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2006
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, ifosfamide, carboplatin, etoposide and thiotepa in germ cell tumor (GCT), sponsored by Masonic Cancer Center. Primary endpoint: Overall Survival at 1 year. Started Dec 2006; status: completed.
02
Drugs
Paclitaxel Micelles for Injectionifosfamidecarboplatinetoposidethiotepa
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00432094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432094.